Table 2.

Major bleeding among DOAC using patients.

Major bleeding
	Concurrent statin	No. of PQs	No. of events	Crude incidence rate (per 1,000 person-year) (95% CI)	Adjusted incidence rate (per 1,000 person-year) (95% CI)	Adjusted IRR (95% CI)	Adjusted IRD (per 1,000 person-year) (95% CI)
All	No statin	332259	4,580	55.69 (53.95–57.48)	50.86 (48.73–53.09)	1
	All intensity	238923	2,289	38.73 (36.03–40.49)	38.71 (37.02–40.48)	0.76 (0.72–0.81)	−12.15 (−14.94 to −9.37)
	High-intensity	79266	796	40.67 (37.70–43.87)	40.62 (37.65–43.82)	0.81 (0.74–0.88)	−9.52 (−13.32 to −5.72)
	Low-to-moderate-intensity	165474	1,568	38.32 (36.33–40.43)	38.30 (36.31–40.40)	0.75 (0.70–0.80)	−12.74 (−15.71 to −9.78)
Male	No statin	190084	2,444	51.89 (49.70–54.19)	47.39 (44.69–50.25)	1
	All intensity	135304	1,260	37.61 (35.41–39.95)	37.58 (35.38–39.92)	0.79 (0.73–0.86)	−9.81 (−13.40 to −6.22)
	High-intensity	45017	434	39.00 (35.21–43.19)	38.93 (35.15–43.11)	0.83 (0.74–0.94)	−7.95 (−12.85 to −3.05)
	Low-to-moderate-intensity	93569	868	37.49 (34.87–40.31)	37.45 (34.83–40.26)	0.79 (0.72–0.87)	−9.96 (−13.80 to −6.12)
Female	No statin	141669	2,133	60.89 (58.12–63.80)	57.39 (53.95–61.06)	1
	All intensity	103070	1,023	40.16 (37.57–42.93)	40.16 (37.57–42.93)	0.70 (0.64–0.77)	−17.24 (−21.68 to −12.79)
	High-intensity	34017	362	43.17 (38.54–48.34)	43.13 (38.51–48.30)	0.76 (0.67–0.87)	−13.52 (−19.56 to −7.48)
	Low-to-moderate-intensity	71558	694	39.27 (36.27–42.51)	39.26 (36.26–42.50)	0.68 (0.62–0.75)	−18.26 (−22.95 to −13.56)

DOAC, direct oral anticoagulant; PQ, person-quarter; CI, confident interval; IRR, incidence rate ratio; IRD, incidence rate difference.